...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Zenith - my take on TNBC and selling a royalty

Hey Fouremm,  Looks like Trodelvy sales cover multiple markets.  It looks like its approved for 3 specific cancer treatments so far.  From the Trodelvy site:

  1. HR+ and HER2 breast cancer
  2. TNBC
  3. Bladder & Urinary tract

 

WHAT IS TRODELVY?

TRODELVY® (sacituzumab govitecan-hziy) is a prescription medicine used to treat adults with:

  • hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative breast cancer that has spread to other parts of the body (metastatic) or cannot be removed by surgery, and who previously received endocrine therapy and at least two additional treatments for metastatic disease
  • triple-negative breast cancer (negative for estrogen and progesterone hormone receptors and HER2) that has spread to other parts of the body or cannot be removed by surgery, and who have received two or more prior treatments, including at least one treatment for metastatic disease.
  • bladder cancer and cancers of the urinary tract that have spread or cannot be removed by surgery, and who have received a platinum-containing chemotherapy medicine and also received an immunotherapy medicine. This indication is approved based on medical studies that measured how many patients responded and how long they responded. Continued approval may depend on benefit demonstrated in additional medical studies.
Share
New Message
Please login to post a reply